FVIIIa Mimetics: New Approaches and Next-Generation Initiatives - PubMed
2 hours ago
- #Emicizumab
- #FVIIIa Mimetics
- #Hemophilia A
- Emicizumab has transformed hemophilia A treatment but has limitations in achieving higher hemostatic efficacy (only equivalent to mild hemophilia) and global accessibility.
- Two key paradigms for future care are Innovation and Access, with innovation focusing on next-generation FVIIIa mimetics like Mim8 (denecimig) and NXT007.
- Mim8 showed superiority over prior prophylaxis in the FRONTIER 2 phase 3 study, offering flexible dosing from weekly to monthly.
- NXT007, using FAST-Ig technology with dual light chains, has potential to achieve non-hemophilic coagulation ranges in Phase 1/2 studies.
- Access strategies include low-dose emicizumab regimens for resource-constrained settings, but these have limitations such as lack of sensitive joint health monitoring and risk of subclinical breakthrough bleeding.
- The review provides a roadmap to advance care standards while addressing global equity in hemophilia A treatment.